GLS Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: GLS Pharma Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $198.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

GLS Pharma Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $198.8K Trade | TransData Nexus

GLS Pharma Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $198.8K Total Trade · DGFT Verified

GLS Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $198.8K across 4 products in 2 therapeutic categories. Based on 45 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cyclophosphamide ($120.3K), Ifosfamide ($47.8K), Busulfan ($18.4K).

GLS Pharma Limited — Export Portfolio & Destination Treemap

GLS Pharma Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is GLS Pharma Limited? — Company Overview & Market Position

GLS Pharma Limited, established on September 1, 2004, is a professionally managed pharmaceutical company headquartered in New Delhi, India. The company specializes in the manufacturing and marketing of oncology and chemotherapy-related products, including chemotherapy, hematology, supportive care, and novel drug delivery systems (NDDS). GLS Pharma has a significant presence in the Indian pharmaceutical market, exporting its products to over 30 countries.

The company operates as a public limited entity with an authorized capital of ₹13 million and a paid-up capital of ₹12 million. As of April 3, 2024, GLS Pharma employed 116 professionals. In June 2022, GLS Pharma was acquired by Aurobindo Pharma, a leading Indian pharmaceutical company, enhancing its capabilities and market reach.

What Does GLS Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Cyclophosphamide$120.3K 2Ifosfamide

Product Portfolio — Top 4 by Export Value

GLS Pharma Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cyclophosphamide	Oncology	$120.3K	32	0.6%	12
2	Ifosfamide	Advanced Oncology	$47.8K	3	2.0%	10
3	Busulfan	Advanced Oncology	$18.4K	5	0.4%	8
4	Chlorambucil	Advanced Oncology	$12.3K	5	3.6%	4

GLS Pharma Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $198.8K. The top category is Oncology (60.5% of portfolio), followed by Advanced Oncology (39.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

GLS Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

GLS Pharma operates a WHO GMP-certified manufacturing facility located in Jeedimetla, Hyderabad, India. This facility specializes in the production of oncology and chemotherapy-related products, ensuring adherence to stringent quality standards. The company's backward integration strategy includes the in-house manufacturing of 38 oncology active pharmaceutical ingredients (APIs), allowing GLS Pharma to control costs without compromising on quality.

3Key Leadership

GLS Pharma's leadership team comprises experienced professionals with extensive backgrounds in the pharmaceutical industry. Suresh Pathak, the founder and director, has over three decades of experience in the sector, having held leadership positions in companies such as Dabur Pharma, Zydus Cadila, MSD, Wockhardt, and Win Medicare. Other key directors include Srinivasa Ramachandra Rao Ilapakurthy, appointed on December 15, 2023, and Ravikiran Namburi, appointed on September 20, 2024.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does GLS Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

GLS Pharma's products are registered and approved in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's focus on high-quality manufacturing and adherence to international standards has facilitated market access in these regions. Specific details regarding regulatory filings and approvals are not publicly disclosed.

2Emerging Markets

GLS Pharma has expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to providing affordable and high-quality oncology products has enabled it to penetrate these regions effectively. While specific information on WHO prequalification is not available, the company's adherence to international quality standards supports its market access in these areas.

3Geographic Strategy

GLS Pharma's geographic strategy involves a balanced approach, focusing on both domestic and international markets. The company's export activities to over 30 countries demonstrate its commitment to global expansion. By diversifying its market presence, GLS Pharma mitigates concentration risk and leverages growth opportunities across different regions.

GLS Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding GLS Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to international quality standards suggests compliance with FDA regulations, facilitating market access in the United States.

2WHO & EU GMP

GLS Pharma's manufacturing facility in Hyderabad is WHO GMP-certified, indicating compliance with international quality standards. While specific information regarding EU GMP certification and EDQM status is not available, the company's focus on quality manufacturing supports its potential for market access in the European Union.

3CDSCO & Indian Regulatory

GLS Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory requirements. The company's adherence to these standards facilitates its operations within India and supports its export activities.

GLS Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

GLS Pharma operates in the competitive oncology pharmaceutical sector, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on high-quality, affordable oncology products positions it as a significant player in the market. The acquisition by Aurobindo Pharma in June 2022 may enhance its competitive position through increased resources and market reach.

2Key Differentiators

GLS Pharma's key differentiators include its backward integration strategy, in-house manufacturing of 38 oncology APIs, and a focus on providing affordable, high-quality oncology products. The company's commitment to quality manufacturing and customer service further distinguishes it in the competitive pharmaceutical landscape.

3Strategic Position

GLS Pharma's strategic direction focuses on the oncology segment, emphasizing the development and marketing of chemotherapy and supportive care products. The company's acquisition by Aurobindo Pharma in June 2022 is expected to strengthen its position in the generics market and may provide opportunities to explore specialty pharmaceuticals and contract development and manufacturing organization (CDMO) services in the future.

Buyer Due Diligence Brief — Evaluating GLS Pharma Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

GLS Pharma demonstrates a strong track record in the pharmaceutical industry, with a focus on quality manufacturing and customer service. The company's export activities to over 30 countries indicate consistent export volume and reliability. The acquisition by Aurobindo Pharma in June 2022 may further enhance its capabilities and reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering GLS Pharma as a supplier:

FDA Registration: Confirm the company's FDA facility registration status to ensure compliance with U.S. regulations.

WHO GMP Certification: Verify the WHO GMP certification of the manufacturing facility to ensure adherence to international quality standards.

EU GMP Certification: Check for EU GMP certification to facilitate market access in the European Union.

Frequently Asked Questions — GLS Pharma Limited

How many pharmaceutical products does GLS Pharma Limited export from India?

GLS Pharma Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Cyclophosphamide ($120.3K), Ifosfamide ($47.8K), Busulfan ($18.4K), Chlorambucil ($12.3K). Total export value is $198.8K.

What is GLS Pharma Limited's total pharmaceutical export value?

GLS Pharma Limited's total pharmaceutical export value is $198.8K, based on 45 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does GLS Pharma Limited cover?

GLS Pharma Limited exports across 2 therapeutic categories. The largest are Oncology (60.5%, 1 products), Advanced Oncology (39.5%, 3 products).

Get Full GLS Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.